Nectin Therapeutics Ltd. (Nectin), a biotechnology firm dedicated to developing innovative targeted immunotherapies to overcome resistance to approved immune oncology treatments, has announced significant advancements in its Phase 1 clinical trial of NTX1088. The company is introducing a combination therapy arm featuring the immune-oncology drug KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy. Additionally, Nectin has expanded the trial to include four new global sites, namely Sheba Medical Center, Hadassah Medical Center, Ochsner Health, and City of Hope, in addition to the flagship site, MD Anderson Cancer Center.
NTX1088, Nectin's First-in-Class lead candidate, is a highly potent monoclonal antibody designed to target PVR (CD155), a transmembrane protein expressed on cancer cells associated with resistance to PD1 and PDL1 immune checkpoint inhibitors. The therapeutic approach of PVR blockade by NTX1088 is groundbreaking, aiming to restore the antitumor immune activity of DNAM1 (CD226). DNAM1, a cell surface glycoprotein crucial to the function of T and NK cells, is degraded by PVR on tumor cells. Blocking PVR with NTX1088 restores the expression and activation of DNAM1, resulting in enhanced antitumor activity from T and NK cells. Furthermore, PVR blockade by NTX1088 stimulates an antitumor immune response by preventing the suppressing signaling of several immune checkpoint receptors, including TIGIT and CD96. Currently, NTX1088 is undergoing clinical evaluation both as a monotherapy and in combination with KEYTRUDA® (pembrolizumab).
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!